Windtree Therapeutics Inc (WINT) Financiero

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 14 full-time employees. The firm is engaged in the biotechnology business, advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. aPKCi inhibitor platform is a potential high-potency, specific, drug candidate with applications in oncology, particularly in hedgehog pathway-dependent cancers. The firm also has a licensing business model with partnership out-licenses in place. The firm is also focused on environmental services space.